ALK and non-small cell lung carcinoma: Various oncogenic driver mutations have been identified in NSCLC, with some of the most common being activating mutations in epidermal growth factor receptor (EGFR) and fusion proteins involving anaplastic lymphoma kinase (ALK) [2,3].